BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Eganelisib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Eganelisib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06533761-2908@assetmemo.bio
DTSTAMP:20261121T005449Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Eganelisib: Phase 1 readout est. (NCT06533761)
DESCRIPTION:Eganelisib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Eganelis
 ib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractor
 y AML/HR-MDS and in Combination With Azacitidine in Previously Untreated H
 R-MDS\nEstimated primary completion: 15 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/eganelisib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06533761
URL:https://assetmemo.bio/drug/eganelisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07439211-2908@assetmemo.bio
DTSTAMP:20261121T005449Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Eganelisib: Phase 1 readout est. (NCT07439211)
DESCRIPTION:Eganelisib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Assessin
 g PI3K Gamma Inhibition With Azacitidine\, Venetoclax and Eganelisib in Pa
 tients With Acute Myeloid Leukemia\nEstimated primary completion: 1 Februa
 ry 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/eganelisib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07439
 211
URL:https://assetmemo.bio/drug/eganelisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
